Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program
Krum H, Curtis SP, Kaur A, Wang H, Smugar SS, Weir MR, Laine L, Brater DC, Cannon CP. Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program. European Journal Of Heart Failure 2009, 11: 542-550. PMID: 19380329, DOI: 10.1093/eurjhf/hfp054.Peer-Reviewed Original ResearchConceptsCongestive heart failureHistory of CHFHazard ratioHeart failureRisk markersRisk factorsIncidence of CHFRisk of CHFMultivariate analysisCox proportional hazards modelNon-steroidal anti-inflammatory drugsBaseline risk factorsHistory of hypertensionEmergency room visitsSignificant risk factorsDose-related increaseSignificant risk markerProportional hazards modelAnti-inflammatory drugsImpact of treatmentEtoricoxib 60CHF hospitalizationBaseline factorsRoom visitsCHF eventsCardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study)
Combe B, Swergold G, McLay J, McCarthy T, Zerbini C, Emery P, Connors L, Kaur A, Curtis S, Laine L, Cannon CP. Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). Rheumatology 2009, 48: 425-432. PMID: 19223284, DOI: 10.1093/rheumatology/kep005.Peer-Reviewed Original ResearchConceptsThrombotic CV eventsHazard ratioCV eventsBlood pressureEfficacy parametersMaximum average changeAdverse event discontinuation rateDouble-blind studyMean treatment durationCohort of patientsSystolic blood pressureEtoricoxib 60Cardiovascular safetyGastrointestinal tolerabilityPrimary endpointRA cohortRA patientsTolerability profileAverage changeDiscontinuation ratesOA patientsPatient cohortClinical trialsSimilar efficacyTreatment duration